CN114470050B - A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin - Google Patents
A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin Download PDFInfo
- Publication number
- CN114470050B CN114470050B CN202210277824.8A CN202210277824A CN114470050B CN 114470050 B CN114470050 B CN 114470050B CN 202210277824 A CN202210277824 A CN 202210277824A CN 114470050 B CN114470050 B CN 114470050B
- Authority
- CN
- China
- Prior art keywords
- honeysuckle
- saxifrage
- radix sophorae
- sophorae flavescentis
- cortex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 210
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 26
- 230000007803 itching Effects 0.000 title claims abstract description 21
- 206010070834 Sensitisation Diseases 0.000 title description 2
- 230000008313 sensitization Effects 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 135
- 239000003814 drug Substances 0.000 claims abstract description 131
- 150000001875 compounds Chemical class 0.000 claims abstract description 129
- 239000002994 raw material Substances 0.000 claims abstract description 106
- 241001647091 Saxifraga granulata Species 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 53
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 208000026935 allergic disease Diseases 0.000 claims abstract description 15
- 230000007815 allergy Effects 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 14
- 230000007794 irritation Effects 0.000 claims abstract description 12
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 18
- 239000000243 solution Substances 0.000 claims description 99
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 63
- 238000002156 mixing Methods 0.000 claims description 48
- 239000002904 solvent Substances 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 33
- 239000002537 cosmetic Substances 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 21
- 238000010298 pulverizing process Methods 0.000 claims description 21
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 19
- 230000003266 anti-allergic effect Effects 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 15
- 230000001139 anti-pruritic effect Effects 0.000 claims description 13
- 239000003908 antipruritic agent Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000002085 irritant Substances 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 230000008439 repair process Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- -1 mask Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 abstract description 33
- 230000036407 pain Effects 0.000 abstract description 4
- 241001570521 Lonicera periclymenum Species 0.000 description 82
- 239000000523 sample Substances 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 27
- 239000012141 concentrate Substances 0.000 description 24
- 239000000843 powder Substances 0.000 description 24
- 230000002757 inflammatory effect Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 108090001007 Interleukin-8 Proteins 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 201000004624 Dermatitis Diseases 0.000 description 9
- 239000012046 mixed solvent Substances 0.000 description 9
- 230000001143 conditioned effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- 240000005001 Paeonia suffruticosa Species 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000182625 Dictamnus albus Species 0.000 description 2
- 241000662429 Fenerbahce Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220156 Saxifraga Species 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 241000220151 Saxifragaceae Species 0.000 description 1
- 206010067723 Skin plaque Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicine compound composition, which contains extracts of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage as raw materials. The invention also provides a method for preparing the traditional Chinese medicine compound composition. The Chinese herbal compound composition can be used for skin care, and is particularly used for preventing and relieving allergy, inflammation, redness, irritation and itching and pain. The invention also relates to the application of the traditional Chinese medicine compound composition in preparing products for resisting allergy, resisting inflammation, relieving redness degree, relieving itching, resisting irritation and/or repairing skin.
Description
Technical Field
The invention relates to a traditional Chinese medicine compound composition, in particular to a traditional Chinese medicine compound composition for resisting allergy, resisting inflammation, relieving redness degree, relieving itching, resisting irritation and/or repairing skin, and more particularly relates to an anti-allergy traditional Chinese medicine compound composition. The Chinese herbal compound composition contains extracts of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage, and can be used for skin care, in particular for preventing and relieving skin allergy, skin inflammation, skin allergy, skin redness, skin irritation and itching pain. The invention also relates to a preparation method of the traditional Chinese medicine compound composition and application thereof in preparing products for resisting allergy, resisting inflammation, relieving redness degree, relieving itching, resisting irritation and/or repairing skin. The invention further relates to a pharmaceutical preparation or a cosmetic containing the traditional Chinese medicine compound composition.
Background
With the increasing deterioration of the environment, excessive use of bad cosmetics and the like, the skin is problematic, for example, inflammation, allergy, chapping, itching and pain are higher and higher in proportion, and how to solve the problems of the skin has great practical significance.
Cortex moutan: the cortex moutan is dried root bark of Paeonia suffruticosa Paeonia suffruticosa Andr. Has effects of promoting blood circulation, removing blood stasis, and clearing heat. Studies have shown that cortex moutan extract can inhibit telangiectasis, permeability increase, and inflammatory early reaction mainly exudative edema. Zhong Yize the three-skin antipruritic soup (capsule) and three-skin acne eliminating soup prepared mainly from cortex Mori, cortex Lycii and cortex moutan are used for treating skin diseases.
Honeysuckle flower: the honeysuckle flower is a dried flower bud or a flower with a primary opening of the honeysuckle Lonicera japonica thunder. Is praised as a good medicine for clearing heat and detoxicating from ancient times. Researches show that the honeysuckle extract mainly contains volatile oil, flavonoid, organic acid, triterpenes and inorganic elements, can be used as raw materials of medicines, health products and cosmetics, and mainly has the effects of inhibiting bacteria, relieving allergy, delaying aging, preventing ultraviolet injury and the like.
Radix Sophorae Flavescentis: is dry root of Sophora flavescens ait Sophora flavescens Ait. Has effects of clearing heat and eliminating dampness, and can be used for treating eczema, skin sore, skin pruritus, etc. Research shows that the kuh-seng extract can inhibit inflammatory cell infiltration of rats, has obvious anti-inflammatory and capillary permeability reducing functions.
Cortex Dictamni Radicis: is dried root bark of Rutaceae plant Dictamnus dasycarpus Dictamnus dasycarpus. Has effects of clearing heat, eliminating dampness, dispelling pathogenic wind, and removing toxic substances, and can be used for treating skin sore due to damp-heat, eczema, rubella, etc. Research shows that it has several activities of resisting bacteria, resisting inflammation, resisting allergy, resisting oxidation, etc.
All-grass of Tiger Saxifraga: is herba Saxifragae Saxifraga stolonifera Curtis belonging to Saxifragaceae, and is a perennial herb. The saxifrage has the effects of dispelling wind, clearing heat, cooling blood, removing toxin, and also has various medicinal values of antibiosis, anti-inflammation, antioxidation, anti-tumor and the like. Research shows that the oxidation resistance of the saxifrage extractive solution at higher concentration is equivalent to that of vitamin C, and has inhibition effect on tyrosinase activity.
At present, research is started focusing on the safer traditional Chinese medicine field, but a plurality of commercial anti-skin allergy agents (particularly cosmetics) have the problems that the efficacy cannot achieve the expected purpose, the product is unstable, and great trouble is brought to users. Thus, there is a strong need for a herbal compound composition that is clearly effective, safe, free of adverse reactions, anti-allergic, anti-inflammatory, soothing to redness, antipruritic, anti-irritant and/or skin repair.
Disclosure of Invention
The invention solves the problems in the prior art through the traditional Chinese medicine compound composition containing cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage, the preparation method and the application thereof. The invention provides a traditional Chinese medicine compound composition with strong anti-allergy, anti-inflammatory, relieving redness degree, relieving itching, anti-irritation and/or skin repairing effects. The Chinese herbal compound composition of the invention contains cortex moutan, honeysuckle, kuh-seng, cortex dictamni and/or saxifrage. The Chinese herbal compound composition can be used for skin care, and is particularly used for preventing and relieving skin allergy, skin inflammation, skin allergy, skin redness, skin irritation and itching pain.
The first aspect of the invention relates to a traditional Chinese medicine compound composition, which contains or consists of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage.
In some embodiments, in the traditional Chinese medicine compound composition of the invention, the composition contains the following bulk drugs in percentage by weight: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage; or consist of them.
In a second aspect the invention relates to a method for preparing a compound Chinese herbal composition comprising the bulk drugs described in the first aspect and their weight percentages.
In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: weighing and crushing raw materials, wherein the raw materials comprise cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage; extracting the crushed raw materials with water, extracting with 10-70% aqueous solution of C2-6 alcohol, and mixing the two extracts to obtain an extract composition. In some embodiments, the method further comprises purifying the resulting extract composition by filtration and obtaining a concentrate, i.e., the herbal compound composition of the invention.
In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: respectively weighing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae, and pulverizing; the crushed raw materials are extracted according to the following methods: firstly extracting with water, then extracting with 10% -70% of aqueous solution containing C2-6 alcohol, mixing the two extracts to obtain each individual crude drug extract. In some embodiments, the method further comprises purifying the resulting individual drug substance extracts by filtration and obtaining a concentrate, and mixing the individual drug substance extracts according to the following weight percentages of each individual drug substance extract: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage, thus obtaining the traditional Chinese medicine compound composition.
A third aspect of the present invention relates to a compound Chinese herbal composition of the present invention obtained by the preparation method as defined in the second aspect of the present invention. In some embodiments, the herbal compound composition comprises cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae. Further, the herbal compound composition is as defined in the first aspect of the invention.
A fourth aspect of the present invention relates to a compound Chinese medicinal composition for antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant and/or skin repair. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by a preparation method as defined in the third aspect of the invention.
In a fifth aspect the present invention relates to the use of a herbal compound composition in a product for antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant and/or skin repair. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by a preparation method as defined in the third aspect of the invention. In some embodiments, the product is a pharmaceutical formulation or a cosmetic.
In a sixth aspect the present invention relates to a pharmaceutical preparation or cosmetic, wherein the pharmaceutical preparation or cosmetic comprises or consists of a herbal compound composition comprising cortex moutan, honeysuckle, kuh-seng, cortex dictamni and/or saxifrage.
In a seventh aspect the invention relates to a cosmetic method comprising applying a compound composition comprising cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage.
Drawings
FIG. 1 shows the inhibition of inflammatory factor IL-8 by the compound Chinese medicinal compositions of example 3 and comparative examples 1-4 at different concentrations.
FIG. 2 shows the inhibition of inflammatory factor NF-kb by the herbal compound compositions of example 3 and comparative examples 1-4 at different concentrations.
FIG. 3 shows the effect of different concentrations of the compound Chinese medicinal compositions of example 3 and comparative examples 1-4 on the change in the redness of human skin after 24 hours.
Detailed Description
Definition of the definition
The terms "Chinese medicinal composition", "Chinese herbal compound composition" and "composition" as used herein have similar meanings and are used interchangeably unless otherwise indicated. The terms "wt%" and "weight percent" are used interchangeably herein, and refer to weight percent unless otherwise specified.
The term "room temperature" as used herein refers to 25 ℃ ± 1 ℃. Meanwhile, unless the experimental temperature is specifically indicated, the experimental temperature is room temperature.
The terms "s", "min" and "h" as used herein represent "seconds", "minutes" and "hours", respectively.
The term "about" as used herein refers to + -10%, more preferably + -5%, and most preferably + -2% of the value modified by the term, so that a person of ordinary skill in the art will be able to determine the scope of the term "about" based on the value modified.
The term "consisting of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage" as used herein means that other active ingredients are not contained except the defined cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage, but auxiliary ingredients such as auxiliary materials, excipients and carriers are not excluded.
The term "pulverizing the raw materials" as used herein means pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae together or separately.
The first aspect of the invention relates to a traditional Chinese medicine compound composition, which contains or consists of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage.
In some embodiments, the cortex moutan, the honeysuckle, the radix sophorae flavescentis, the cortex dictamni and/or the saxifrage in the traditional Chinese medicine compound composition are selected from the following raw materials in percentage by weight: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 33.3%, 33.4%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% and a range between any of the above weight percentages, for example, in the present invention, the following composition comprises the following weight percentages of the raw materials: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 0-20% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12-28% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12-24% of cortex moutan, 20-28% of honeysuckle, 20-24% of radix sophorae flavescentis, 20-28% of cortex dictamni and/or 2-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 18-24% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 24-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 24-28% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 4-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and/or 2% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 18% of cortex moutan, 20% of honeysuckle, 28% of radix sophorae flavescentis, 28% of cortex dictamni and/or 6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and/or 4% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: cortex moutan 28%, flos Lonicerae 20%, radix Sophorae Flavescentis 24%, cortex Dictamni Radicis 20% and/or herba Saxifragae 8%; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and/or 4% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 18% of cortex moutan, 20% of honeysuckle, 28% of radix sophorae flavescentis, 28% of cortex dictamni and 6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 28% of cortex moutan, 20% of honeysuckle, 24% of radix sophorae flavescentis, 20% of cortex dictamni and 8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw materials in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage; or consist of them.
In a second aspect the invention relates to a method for preparing a compound Chinese herbal composition comprising the bulk drugs described in the first aspect and their weight percentages.
In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: weighing and crushing raw materials, wherein the raw materials comprise cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage; extracting the crushed raw materials with water, extracting with 10-70% aqueous solution of C2-6 alcohol, and mixing the two extracts to obtain an extract composition. In some embodiments, the method further comprises purifying the resulting extract composition by filtration and obtaining a concentrate, i.e., the herbal compound composition of the invention.
In some embodiments, the preparation method of the traditional Chinese medicine compound composition comprises the following steps: respectively weighing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae, and pulverizing; the crushed raw materials are extracted according to the following methods: firstly extracting with water, then extracting with 10% -70% of aqueous solution containing C2-6 alcohol, mixing the two extracts to obtain each individual crude drug extract. In some embodiments, the method further comprises the steps of purifying the obtained single raw material medicine extracts through filtration, obtaining concentrated solutions, and mixing the cortex moutan extract, the honeysuckle extract, the radix sophorae flavescentis extract, the cortex dictamni extract and/or the saxifrage extract according to a certain weight percentage ratio, so as to obtain the traditional Chinese medicine compound composition. Specifically, the certain proportion is selected from the following weight percentages: 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 33.3%, 33.4%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99% and a range between any of the above weight percentages, for example, in a Chinese herbal compound composition of the present invention, said composition comprises the following weight percentages of the extract as raw materials: 0-40% of cortex moutan, 0-60% of honeysuckle, 0-60% of radix sophorae flavescentis, 0-80% of cortex dictamni and/or 0-40% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 0-20% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-28% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 20-28% of honeysuckle, 20-24% of radix sophorae flavescentis, 20-28% of cortex dictamni and/or 2-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 18-24% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 24-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 24-28% of cortex dictamni and/or 2-8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and/or 4-6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and/or 2% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 18% of cortex moutan, 20% of honeysuckle, 28% of radix sophorae flavescentis, 28% of cortex dictamni and/or 6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and/or 4% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: cortex moutan 28%, flos Lonicerae 20%, radix Sophorae Flavescentis 24%, cortex Dictamni Radicis 20% and/or herba Saxifragae 8%; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and/or 4% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 18% of cortex moutan, 20% of honeysuckle, 28% of radix sophorae flavescentis, 28% of cortex dictamni and 6% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 28% of cortex moutan, 20% of honeysuckle, 24% of radix sophorae flavescentis, 20% of cortex dictamni and 8% of saxifrage; in the traditional Chinese medicine compound composition, the composition contains the following raw material medicine extracts in percentage by weight: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage; or consist of them. In some embodiments, the concentrates are conditioned with water. Further, each of the concentrates is adjusted to a desired amount, for example, 1000g, with water.
In some embodiments, the extract composition is filtered through a filter membrane for purification and a concentrate is obtained. In some embodiments, the filtrate is collected by filtration through an ultrafiltration membrane of 5000 to 10000 daltons. In some embodiments, the solvent is recovered by filtration through a nanofiltration membrane of 100 to 1000 daltons to provide a concentrate.
In some embodiments, the extract of the present invention is a water and/or C2-6 alcohol extract and the extraction solvent is water, a C2-6 alcohol, or a combination thereof. In some embodiments, the C2-6 alcohol is ethanol, propanol, propylene glycol, n-butanol, or a combination thereof, preferably propylene glycol and ethanol. In some embodiments, the crude drug is crushed, extracted with water, then extracted with 10% -70% aqueous solution of C2-6 alcohol, and the two extracts are mixed to obtain an extract composition. In a further preferred embodiment, the aqueous extract of the crushed crude drug is extracted with 10% -50% aqueous solution of C2-6 alcohol, and the two extracts are mixed to obtain the extract composition.
In some embodiments, the crude drug is crushed, extracted with water, then extracted with 10% -70% aqueous solution of propylene glycol and/or ethanol, and then the two extracts are mixed to obtain the extract composition. In some embodiments, the crude drug is crushed, extracted with water, then extracted with 10% -50% aqueous solution of propylene glycol and/or ethanol, and then the two extracts are mixed to obtain the extract composition.
In some embodiments, the method comprises pulverizing the raw materials into 10-20 mesh coarse powder, adding 5-10 times of water, extracting at 50-90deg.C to obtain extractive solution A1. Extracting the residue with 2-10 times of ethanol, propanol, propylene glycol, n-butanol or their combination at 50-90deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution. In some embodiments, the extract composition is filtered through a filter membrane for purification and a concentrate is obtained. In some embodiments, the filtrate is collected by filtration through an ultrafiltration membrane of 5000 to 10000 daltons. In some embodiments, the solvent is recovered by filtration through a nanofiltration membrane of 100 to 1000 daltons to provide a concentrate.
In some embodiments, the method comprises pulverizing the raw materials into 10-20 mesh coarse powder, adding 5-10 times of water for extraction at 50-90deg.C to obtain extract A1; extracting the residue with 2-10 times of ethanol, propanol, propylene glycol, n-butanol or their combination at 50-90deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution. In some embodiments, the drug substance is pulverized into 10 mesh or 20 mesh coarse powder. In some embodiments, extraction is performed by adding water in a range of 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, or a multiple thereof at a temperature of 50 ℃, 60 ℃, 70 ℃, 80 ℃, 90 ℃, or a temperature range therebetween, to obtain extract A1. In some embodiments, the residue is extracted with ethanol or propylene glycol or a mixture of ethanol and propylene glycol (at 1:1) in a range of 2-fold, 3-fold, 4-fold, or a multiple thereof at a temperature of 50 ℃, 55 ℃, 60 ℃, 65 ℃, 70 ℃, 80 ℃, 90 ℃, or a temperature range therebetween to obtain extract A2. In some embodiments, the ethanol or propylene glycol or mixture of ethanol and propylene glycol (1:1 volume percent) is 10% to 70% ethanol or propylene glycol or mixture of ethanol and propylene glycol (1:1 volume percent). In some embodiments, the ethanol or propylene glycol or mixture of ethanol and propylene glycol (in 1:1 volume percent) is 10%, 20%, 30%, 40%, 50% or a range therebetween. In some embodiments, the concentrate is adjusted to 1000g with water, i.e., representing an extract with a concentration of 100%.
In some embodiments, the method comprises pulverizing the crude drug into 10 mesh coarse powder, adding about 6 times of water for extraction at about 60 ℃ to obtain an extract A1; extracting the residue with about 3 times of about 40% propylene glycol at about 70deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises pulverizing the crude drug into 20 mesh coarse powder, adding about 5 times of water for extraction at about 80deg.C to obtain extract A1; extracting the residue with about 3 times of about 40% ethanol at 65deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises pulverizing the crude drug into 20 mesh coarse powder, adding about 5 times of water for extraction at about 60 ℃ to obtain an extract A1; extracting the residue with a 1:1 mixed solvent of 10% ethanol and 40% propylene glycol at 70deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises pulverizing the crude drug into 20 mesh coarse powder, adding about 5 times of water for extraction at about 70deg.C to obtain extract A1; extracting the residue with a mixed solvent of 40% ethanol and 10% propylene glycol at 55deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises pulverizing the crude drug into 10 mesh coarse powder, adding about 6 times of water for extraction at about 60 ℃ to obtain an extract A1; extracting the residue with about 3 times 40% propylene glycol solvent at 70deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises pulverizing the crude drug into 20 mesh coarse powder, adding about 5 times of water for extraction at about 80deg.C to obtain extract A1; extracting the residue with about 3 times of 40% ethanol solvent at 65deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises pulverizing the crude drug into 20 mesh coarse powder, adding about 5 times of water for extraction at about 70deg.C to obtain extract A1; extracting the residue with a mixed solvent of 40% ethanol and 10% propylene glycol at 55deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution.
In some embodiments, the method comprises respectively taking cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae, respectively taking the raw materials, pulverizing into 10 mesh coarse powder, adding about 6 times of water, extracting at about 60deg.C to obtain extractive solution A1; extracting the residue with about 3 times of about 40% propylene glycol at about 70 ℃ to obtain an extract A2, mixing the extract A1 and the extract A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 12% of cortex moutan, 32% of honeysuckle, 20% of radix sophorae flavescentis, 36% of cortex dictamni and 2% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
In some embodiments, the method comprises respectively pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, extracting at about 80deg.C to obtain extractive solution A1; extracting the residue with about 3 times of about 40% ethanol at 65deg.C to obtain extractive solution A2. Mixing the extracting solutions A1 and A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material medicine extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 18% of cortex moutan, 20% of honeysuckle, 28% of radix sophorae flavescentis, 28% of cortex dictamni and 6% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
In some embodiments, the method comprises respectively pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, extracting at about 60deg.C to obtain extractive solution A1; extracting the residue with a 1:1 mixed solvent of 10% ethanol and 40% propylene glycol at 70deg.C to obtain extractive solution A2. Mixing the extracting solutions A1 and A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material medicine extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
In some embodiments, the method comprises respectively pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, extracting at about 70deg.C to obtain extractive solution A1; extracting the residue with a mixed solvent of 40% ethanol and 10% propylene glycol at 55deg.C to obtain extractive solution A2. Mixing the extracting solutions A1 and A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material medicine extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 28% of cortex moutan, 20% of honeysuckle, 24% of radix sophorae flavescentis, 20% of cortex dictamni and 8% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
In some embodiments, the method comprises respectively taking cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae, respectively taking the raw materials, pulverizing into 10 mesh coarse powder, adding about 6 times of water, extracting at about 60deg.C to obtain extractive solution A1; extracting the residue with about 3 times 40% propylene glycol solvent at 70deg.C to obtain extractive solution A2. Mixing the extracting solutions A1 and A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material medicine extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
In some embodiments, the method comprises respectively taking cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae, respectively taking the raw materials, pulverizing into 20 mesh coarse powder, adding about 5 times of water, extracting at about 80deg.C to obtain extractive solution A1; extracting the residue with about 3 times of 40% ethanol solvent at 65deg.C to obtain extractive solution A2. Mixing the extracting solutions A1 and A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material medicine extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
In some embodiments, the method comprises respectively pulverizing cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis, and herba Saxifragae into 20 mesh coarse powder, respectively, adding about 5 times of water, extracting at about 70deg.C to obtain extractive solution A1; extracting the residue with a mixed solvent of 40% ethanol and 10% propylene glycol at 55deg.C to obtain extractive solution A2. Mixing the extracting solutions A1 and A2, filtering, recovering the solvent to obtain concentrated solutions of the raw material medicine extracts, and combining according to a certain weight percentage ratio to obtain the traditional Chinese medicine compound composition. The certain proportion of each extract is as follows by weight percent: 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage. In some embodiments, the concentrate is conditioned with water. Further, the concentrate was adjusted to 1000g with water.
A third aspect of the present invention relates to a compound Chinese herbal composition of the present invention obtained by the preparation method as defined in the second aspect of the present invention. In some embodiments, the traditional Chinese medicine compound composition obtained by the method has the functions of resisting allergy, resisting inflammation, relieving redness degree, relieving itching, resisting irritation and/or repairing skin. In some embodiments, the allergy, inflammation, redness, itching, irritation is caused by inflammatory factors. In some embodiments, the inflammatory factors are IL-8 and NF-kb. In some embodiments, the herbal compound composition comprises cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and/or herba Saxifragae. Further, the herbal compound composition is as defined in the first aspect of the invention.
A fourth aspect of the present invention relates to a compound Chinese medicinal composition for antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant and/or skin repair. In some embodiments, the allergy, inflammation, redness, itching, irritation is caused by inflammatory factors. In some embodiments, the inflammatory factors are IL-8 and NF-kb. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by a preparation method as defined in the third aspect of the invention.
In a fifth aspect the present invention relates to the use of a herbal compound composition in a product for antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant and/or skin repair. In some embodiments, the allergy, inflammation, redness, itching, irritation is caused by inflammatory factors. In some embodiments, the inflammatory factors are IL-8 and NF-kb. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by a preparation method as defined in the third aspect of the invention. In some embodiments, the product is a pharmaceutical formulation or a cosmetic.
In a sixth aspect the present invention relates to a pharmaceutical preparation or cosmetic, wherein the pharmaceutical preparation or cosmetic comprises or consists of a herbal compound composition comprising cortex moutan, honeysuckle, kuh-seng, cortex dictamni and/or saxifrage. In some embodiments, the pharmaceutical formulation or cosmetic has antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant and/or skin-repairing effects. In some embodiments, the allergy, inflammation, redness, itching, irritation is caused by inflammatory factors. In some embodiments, the inflammatory factors are IL-8 and NF-kb. In some embodiments, the pharmaceutical or cosmetic formulation comprises a herbal compound composition as an active ingredient, as well as one or more cosmetically or pharmaceutically acceptable carriers, diluents or excipients. In some embodiments, the pharmaceutical formulation or cosmetic is a cream, lotion, paste, ointment, mask, gel, lotion, or serum. In some embodiments, the pharmaceutical or cosmetic formulations of the present invention may also contain one or more other ingredients, such as plant extracts, nutritional additives, surfactants, fragrances and perfumes, pigments, preservatives, antioxidants, moisturizers, ultraviolet absorbers, astringents, permeation aids, pH adjusting agents, and the like. The skilled person will be able to choose according to their general knowledge and specific needs. In some embodiments, the herbal compound composition comprises about 0.1-20%, preferably 2-15%, more preferably 5-10% by weight of the pharmaceutical formulation or cosmetic.
In a seventh aspect the invention relates to a cosmetic method comprising applying a compound composition comprising cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage. In some embodiments, the cosmetic method has antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant, and/or skin-rejuvenating effects. In some embodiments, the allergy, inflammation, redness, itching, irritation is caused by inflammatory factors. In some embodiments, the inflammatory factors are IL-8 and NF-kb. In some embodiments, the present invention relates to a cosmetic method comprising applying a pharmaceutical formulation or cosmetic comprising the herbal compound composition. In some embodiments, the herbal compound composition is as defined in the first aspect of the invention. In some embodiments, the herbal compound composition is a herbal compound composition obtained by a preparation method as defined in the third aspect of the invention. In some embodiments, the pharmaceutical formulation or cosmetic is as defined in the sixth aspect of the invention.
The beneficial effects of the invention are as follows:
the Chinese herbal compound composition containing cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and/or saxifrage and the pharmaceutical preparation or cosmetic containing the composition have unexpected technical effects, particularly have strong effects of resisting allergy, resisting inflammation, relieving redness degree, relieving itching, resisting stimulation and/or repairing skin, and the extracts containing the five raw materials have obviously improved beneficial effects on skin and better synergistic effect compared with the extracts containing the four raw materials.
Alternatively, the extracts may be obtained by separately extracting the individual raw materials, and then combining the obtained extracts, thereby obtaining the extract composition of the present invention. The crude drug may be extracted by a known extraction method, but preferably, the extraction is performed by the method described in the specification of the present invention. The product prepared by the method has the functions of strong antiallergic, anti-inflammatory, relieving redness degree, relieving itching, anti-irritation and/or repairing skin, and is more stable, safer and free of side effects.
Detailed Description
The present invention can be carried out by the following embodiments, but the present invention is not limited thereto.
Percentages referred to in embodiments of the invention, such as without explicit indication, are weight percentages.
The instruments used in the embodiments of the present invention are all conventional in the art and may be replaced with instruments conforming to the corresponding standards.
Reagents employed in embodiments of the invention are commercially available analytically pure reagents unless explicitly indicated.
The raw materials and instruments mentioned in the present invention are all common in the art, and are only examples, and are not intended to limit the protection scope of the present invention. Those skilled in the art can select equivalent raw materials and related instrumentation based on the present disclosure.
1. Preparation of traditional Chinese medicine compound composition
Example 1
Taking 1000g of raw materials, wherein the root bark of tree peony is 12%, the honeysuckle is 32%, the kuh-seng is 20%, the cortex dictamni is 36% and the saxifrage is 2%, crushing into 10-mesh coarse powder, adding water with the concentration of about 6 times for extraction, and obtaining an extract A1 at the extraction temperature of about 60 ℃; extracting the residue with about 3 times of about 40% propylene glycol at about 70deg.C to obtain extractive solution A2; mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 2
Taking 1000g of raw materials, wherein 18% of cortex moutan, 20% of honeysuckle, 28% of radix sophorae flavescentis, 28% of cortex dictamni and 6% of saxifrage, crushing into coarse powder of 20 meshes, adding water of about 5 times for extraction, and obtaining an extracting solution A1 at the extraction temperature of about 80 ℃; extracting the residue with about 3 times of about 40% ethanol at 65deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 3
Taking 1000g of raw materials, wherein 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage, crushing into coarse powder of 20 meshes, adding water of about 5 times for extraction, and obtaining an extracting solution A1 at the extraction temperature of about 60 ℃; extracting the residue with a 1:1 mixed solvent of 10% ethanol and 40% propylene glycol at 70deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 4
Taking 1000g of raw materials, wherein the root bark of tree peony is 28%, the honeysuckle is 20%, the kuh-seng is 24%, the cortex dictamni is 20% and the saxifrage is 8%, crushing into coarse powder of 20 meshes, adding water of about 5 times for extraction, and obtaining an extracting solution A1 at the extraction temperature of about 70 ℃; extracting the residue with a mixed solvent of 40% ethanol and 10% propylene glycol at 55deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 5
Taking 1000g of raw materials, wherein 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage, crushing into 10-mesh coarse powder, adding about 6 times of water for extraction, and obtaining an extracting solution A1 at the extraction temperature of about 60 ℃; extracting the residue with about 3 times 40% propylene glycol solvent at 70deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 6
Taking 1000g of raw materials, wherein 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage, crushing into coarse powder of 20 meshes, adding water of about 5 times for extraction, and obtaining an extracting solution A1 at the extraction temperature of about 80 ℃; extracting the residue with about 3 times of 40% ethanol solvent at 65deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 7
Taking 1000g of raw materials, wherein 24% of cortex moutan, 28% of honeysuckle, 20% of radix sophorae flavescentis, 24% of cortex dictamni and 4% of saxifrage, crushing into coarse powder of 20 meshes, adding water of about 5 times for extraction, and obtaining an extracting solution A1 at the extraction temperature of about 70 ℃; extracting the residue with a mixed solvent of 40% ethanol and 10% propylene glycol at 55deg.C to obtain extractive solution A2. Mixing the extractive solutions A1 and A2, mixing, filtering, and recovering solvent to obtain concentrated solution, and adjusting the concentration with water to 1000g to obtain 100% extractive solution.
Example 8
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 1 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 1 to finally obtain the composite extract with the marked concentration of 100%.
Example 9
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 2 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 2 to finally obtain the composite extract with the marked concentration of 100%.
Example 10
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 3 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 3 to finally obtain the composite extract with the marked concentration of 100%.
Example 11
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 4 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 4 to finally obtain the composite extract with the marked concentration of 100%.
Example 12
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 5 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 5 to finally obtain the composite extract with the marked concentration of 100%.
Example 13
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 6 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 6 to finally obtain the composite extract with the marked concentration of 100%.
Example 14
Respectively taking 1000g of the raw materials of cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage, respectively extracting according to the method of the embodiment 7 to finally obtain 1000g of the extract with the marked concentration of 100%, and then combining according to the proportion of the embodiment 7 to finally obtain the composite extract with the marked concentration of 100%.
Comparative example 1
1000g of raw materials are taken, wherein, 26% of honeysuckle, 26% of kuh-seng, 36% of dittany bark and 12% of saxifrage are extracted by adopting a method similar to that of the example 3.
Comparative example 2
1000g of the raw materials are taken, wherein the root bark of tree peony is 26%, the kuh-seng is 28%, the cortex dictamni is 38%, and the saxifrage is 8%, and the extraction is carried out by adopting the method similar to the method of the example 3.
Comparative example 3
1000g of the raw materials are taken, wherein 26% of cortex moutan, 30% of honeysuckle, 34% of cortex dictamni and 10% of saxifrage are extracted by a method similar to that of the example 3.
Comparative example 4
1000g of the raw materials are taken, wherein the cortex moutan is 28%, the honeysuckle is 32%, the radix sophorae flavescentis is 28%, and the saxifrage is 12%, and the extraction is carried out by adopting a method similar to that of the embodiment 3.
2. In vivo efficacy test comparison
Reagent source: sodium dodecyl sulfate (Adamas), hydrocortisone cream (lake south dinor pharmaceutical Co., ltd.), dextran (Adamas), xylene (great)
And (3) preparation of a reagent:
5% (w/w) of sample to be tested: 5g of the 100% strength extract prepared in examples 1 to 4 was added to 95g of physiological saline to prepare 5% (w/w) of each sample to be tested.
5% (w/w) of each comparative example test sample: 5g of the 100% strength extract prepared in comparative examples 1 to 4 was added to 95g of physiological saline to prepare 5% (w/w) of each sample to be tested in comparative examples.
(1) Anti-allergic test (guinea pig irritation)
The dosage of the hydrocortisone cream is 0.1 g/dose by taking 5% sodium dodecyl sulfate as a model group and hydrocortisone cream (specification: 100g/10 mg) as a positive control group. Physiological saline is used as a negative control sample (negative control module), the experimental sample group is 5% (w/w) of the samples to be tested of each example or comparative example, and the dosage is 0.5 g/sample. Samples of the experimental group, the positive control group and the negative control group are respectively mixed with 5% sodium dodecyl sulfate, and are smeared and observed and counted according to the method of multiple skin irritation test of 2015 edition of cosmetic safety technical Specification, P490-491, 6 guinea pigs in each group and each half of male and female. And observing the red and swollen state of the smearing part. The redness and swelling were 4-5 min, the slight redness and swelling was 1-3 min, and the no change was 0 min.
(2) Anti-allergic test (dextran method)
Healthy mice with the weight of 18-22 g are divided into male and female halves randomly according to the weight of sex, and 10 mice are in each group. The animal was then dehaired with 1% sodium sulfide and the dehaired skin area was 1.5cm x 1.5cm for 2 days for the experiment. The dehairing areas on the backs of the animals in each group are respectively and locally smeared with a sample to be detected (1 g/kg). Hydrocortisone cream (specification: 100g/10 mg) was used as a positive control group at a dose of 0.1 g/dose. The extracts prepared in examples or comparative examples were used as a negative control sample (negative control module) in the form of physiological saline, and the experimental sample set was 5% (w/w). For 5 consecutive days, 30min after the last administration, dextran was intravenously injected at 0.95mg/kg in each mouse tail. The number of times of itching in the 30 minutes was recorded by taking the head of the front paw, trunk of the rear paw and various parts of the whole body of the mouth as itching indicators.
The pruritus inhibition ratio = (number of pruritus in negative control group-number of pruritus in sample group)/(number of pruritus in negative control group) 100%.
(3) Anti-inflammatory test (xylene-induced mouse auricle swelling experiment)
Healthy mice with the weight of 18-22 g are divided into male and female halves randomly according to the weight of sex, and 10 mice are in each group. The right ear of the mice was coated with each group of samples to be tested, 0.2 g/mouse, once daily for 3 consecutive days. Hydrocortisone cream (specification: 100g/10 mg) was used as a positive control group at a dose of 0.1 g/dose. The extracts prepared in examples or comparative examples were used as a negative control sample (negative control module) in the form of physiological saline, and the experimental sample set was 5% (w/w). 30min after the last administration, 0.02 ml/piece of 100% xylene inflammatory liquid is coated on the front and back sides of the right ear of the mouse, the left ear is not treated at all, the animal is sacrificed after 4 hours, ears are cut off immediately, the ears at the same position are taken out by an 8mm puncher, the ears are weighed on an analytical balance, the weight of the left ear is subtracted from the weight of the right ear to be the swelling degree, and the (weight of the right ear-weight of the left ear)/weight of the left ear is multiplied by 100% to be the ear swelling rate.
Experimental results
TABLE 1 anti-allergic anti-inflammatory test results
From the results of the table, the Chinese herbal compound composition containing the specific components has synergistic effect in antiallergic, anti-inflammatory, antipruritic, anti-irritant and/or skin repairing aspects.
3. In vitro efficacy test comparison
(1) Anti-inflammatory test (study of inhibition of inflammatory factor IL-8)
N-Hacat cells, DMEM culture Solution (SIGMA), serum, incubator (Simer fly), fluorescent enzyme-labeled instrument (Mega MD), IL-8 detection kit (SIGMA), cell lysate, DPBS (Dulbecco phosphate buffer solution), pancreatin (SIGMA), 96-well plate.
Sample to be measured
Sample to be tested of example 3: sample concentration 0.05%, 0.1%, 0.5% (v/v). The sample of the volume concentration was prepared by adding an appropriate amount of the 100% labeled extract prepared in example 3 to DMEM medium.
Comparative examples 1-4 were prepared in the same manner as the samples to be tested. The sample concentrations were 0.05%, 0.1%, 0.5%.
Reagent: epigallocatechin gallate (EGCG, 50 uM), TNF- α (10 ng/ml).
Experimental method
Taking out cultured N-Hacat cells from the incubator, digesting and centrifuging to obtain suspension, and adjusting cell density to 1×10 5 From about 5 to about 10 per ml 5 Each well is 135 mu.l, and the culture is continued for 12-24 hours by inoculating 96-well plates. After culturing was completed, 15. Mu.l of each concentration of the sample to be tested (extract of example 3, extracts of comparative examples 1 to 4, EGCG with DPBS as negative control) was added to the well plate, and after culturing was continued for 12 to 24 hours, 16.5. Mu.l of TNF-. Alpha.was added to each well of the well plate (16.5. Mu.l of DPBS was added to each well of the control). Culturing for 12-24 hr, collecting culture solution after culturing, using IL-8 detection kit (purchased from SIGMA), operating according to kit specification, and reading at OD450nm with a fluorescence enzyme-labeled instrument.
Experimental results
Experimental results show that the extract of example 3 and the extracts of comparative examples 1-4 have a certain degree of inhibition on the release of inflammatory factor IL-8. With increasing concentration, example 3 showed a more pronounced inhibition P <0.001 of the release of inflammatory factor IL-8 and was dose dependent. However, the comparative example group did not show a significant inhibition of the release of inflammatory factor IL-8. See fig. 1 for specific experimental data.
(2) Anti-inflammatory test (study of inhibition of inflammatory factor NF-kb)
Experimental reagent and equipment
N-Hacat cells, DMEM broth (SIGMA), serum, incubator (Simer fly), fluorescent enzyme-labeled instrument (Megu MD), luciferase assay kit (available from Shanghai Yiying Biotechnology Co., ltd.), cell lysate (available from luciferase assay kit), DPBS (Dulbecco phosphate buffer solution), pancreatin (SIGMA), 96 well plates.
Sample to be measured
Sample to be tested of example 3: sample concentration 0.05%, 0.1%, 0.5% (v/v). The sample to be tested with the volume concentration is prepared by taking a proper amount of the extracting solution with the marked concentration of 100% prepared in the embodiment 3, and adding the extracting solution into the DMEM culture solution.
Comparative examples 1-4 were prepared in the same manner as the samples to be tested. The sample concentrations were 0.05%, 0.1%, 0.5%.
Experimental method
Taking out cultured N-Hacat cells from the incubator, digesting and centrifuging to obtain suspension, and adjusting cell density to 1×10 5 From about 5 to about 10 per ml 5 Each well is 135 mu.l, and the culture is continued for 12-24 hours by inoculating 96-well plates. After culturing was completed, 15. Mu.l of each concentration of the sample to be tested (the mixed extract of example 3, the extracts of comparative examples 1 to 4, EGCG, DPBS as a negative control) was added to the well plate, and after culturing was continued for 12 to 24 hours, 16.5. Mu.l of TNF-. Alpha.was added to each well of the well plate (16.5. Mu.l of DPBS was added to each well of the control). Culturing for 12-24 hr, adding 100 μl of lysate (obtained from luciferase detection kit, see kit instructions) into each well of the well plate, operating according to the instructions of luciferase detection kit (obtained from Shanghai Yiying Biotechnology Co., ltd.), and reading in Lum mode of fluorescence microplate reader.
Experimental results
Experimental results show that the extracts of example 3 and the extracts of comparative examples 1-4 have a certain degree of inhibition on the expression of inflammatory factor NF-kb. With increasing concentration, example 3 showed a more pronounced inhibition P <0.001 of the expression of inflammatory factor NF-kb and was dose dependent. However, the comparative example group did not exhibit a significant inhibitory effect on the expression of inflammatory factor NF-kb. See fig. 2 for specific experimental data.
4. Human body efficacy test experiment
Purpose of testing
The ability of the solution of example 3 to sooth was evaluated by a closed patch redness model and the soothing efficacy of comparative examples 1-4 at the same concentration was compared to demonstrate the synergistic efficacy of the compound components of example 3.
Materials and methods
The subjects 19-60 years old of healthy Chinese accord with cosmetic safety technical Specification 2015 edition, 5. Subject selection in human skin patch test, P541.
Test sample
Red-inducing molding agent: sodium dodecyl Sulfate (SIGMA)
Plaque room ware: finn Chamber 8mm
Sample to be tested of example 3: as described in the formulation of the test agent in the body efficacy test, a proper amount of the 100% concentration labeled extract prepared in example 3 was added to the blank emulsion to prepare a sample to be tested with the desired weight concentration, i.e., 5% (w/w).
The preparation method of the samples to be tested of comparative examples 1 to 4 was the same.
Experimental method
Subjects were skin screened (BL) by staff on the back test area. And selecting skin areas without influencing evaluation factors for spot pasting. An erythrogenic templating agent, i.e., sodium dodecyl sulfonate, was added to each plaque device aperture. And applied to the back for 24 hours. In order to prevent the spot tester from falling off, the periphery can be fixed by medical adhesive tapes.
After 24 hours, the erythrogenic modelling drug was removed and evaluated by a clinical dermatologist according to "6. Method" in "skin closed type plaque test skin response grading criteria of Table 1" in "cosmetic safety Specification 2015 edition" human skin plaque test "(erythrogenic-T0.5). The samples were divided into 6 groups: blank (water) group, 5% of example 3, 5% of comparative examples 1-4. Equal amounts of sample were added to each of the different macula cells and applied to the reddish area for 24 hours and then removed, again assessed by the clinician (post-relief-T24).
Experimental results
The establishment of a reddening model of 32 subjects and the efficacy evaluation of the reddening degree of 6 groups of samples are effectively completed, and the results show that:
example 3 the skin redness evaluation value after the treatment of the sample to be tested was significantly reduced, and there was a significant difference (p < 0.05), indicating that the sample to be tested of example 3 had a significant relief of the symptoms of skin redness. There was no significant difference in redness values before and after soothing (p > 0.05) for comparative examples 1-4, indicating that the extracts of comparative examples did not have a relieving effect on the redness symptoms of skin at these concentrations.
The blank (water) had no significant change in redness values before and after the action, indicating that the water as the sample diluent had no effect on relieving redness. In summary, 5% of the solution of example 3 can significantly relieve the redness symptoms of skin, but the extract of comparative example at the same concentration has no obvious effect, which indicates that the traditional Chinese medicine compound composition containing specific components disclosed by the invention has a synergistic effect in relieving the redness degree. See fig. 3 for specific experimental data.
Claims (16)
1. An antiallergic, anti-inflammatory, redness relieving, antipruritic, anti-irritation and skin repairing traditional Chinese medicine compound composition, wherein the composition comprises the following raw materials in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 2-8% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 10-30% of cortex moutan, 20-40% of honeysuckle, 20-40% of radix sophorae flavescentis, 20-60% of cortex dictamni and 2-8% of saxifrage.
2. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 12-28% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 12-28% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage.
3. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 12-24% of cortex moutan, 20-28% of honeysuckle, 20-24% of radix sophorae flavescentis, 20-28% of cortex dictamni and 2-6% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 20-28% of honeysuckle, 20-24% of radix sophorae flavescentis, 20-28% of cortex dictamni and 2-6% of saxifrage.
4. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 18-24% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 18-24% of cortex moutan, 20-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage.
5. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage.
6. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 24-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 24-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 2-8% of saxifrage.
7. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 24-28% of cortex dictamni and 2-8% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 24-28% of cortex dictamni and 2-8% of saxifrage.
8. The compound traditional Chinese medicine composition according to claim 1, wherein the composition comprises the following raw materials in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 4-6% of saxifrage, or the composition comprises the following raw material medicine extracts in percentage by weight: 12-24% of cortex moutan, 28-32% of honeysuckle, 20-28% of radix sophorae flavescentis, 20-36% of cortex dictamni and 4-6% of saxifrage.
9. A method of preparing the herbal compound composition of any one of claims 1-8, the method comprising:
weighing and crushing raw materials, wherein the raw materials comprise cortex moutan, honeysuckle, radix sophorae flavescentis, cortex dictamni and saxifrage; extracting the pulverized materials with water, extracting with 10% -70% aqueous solution containing C2-6 alcohol, mixing the two extracts to obtain extract composition, filtering the extract composition, and recovering solvent to obtain concentrated solution, or
Respectively weighing and pulverizing the raw materials including cortex moutan, flos Lonicerae, radix Sophorae Flavescentis, cortex Dictamni Radicis and herba Saxifragae; the method for extracting the crushed raw materials comprises the following steps of: firstly extracting with water, then extracting with 10% -70% of aqueous solution containing C2-6 alcohol, mixing the two extracts to obtain individual crude drug extracts, then mixing the individual crude drug extracts to obtain an extract composition, filtering the extract composition, and recovering the solvent to obtain a concentrated solution.
10. The method of claim 9, wherein the C2-6 alcohol is ethanol, propanol, propylene glycol, n-butanol, or a combination thereof; extracting with water at 50-100deg.C; the extraction temperature is 40-85 ℃ by using aqueous solution containing 10-70% of C2-6 alcohol.
11. The compound Chinese medicinal composition for resisting allergy, relieving inflammation, relieving redness, relieving itching, resisting irritation and repairing skin prepared by the method according to claim 9 or 10.
12. Use of a compound composition of traditional Chinese medicine according to any one of claims 1-8 and 11 for the preparation of pharmaceutical preparations or cosmetics for antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant, repairing skin.
13. An antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant, skin-repairing cosmetic comprising, as active ingredient, a herbal compound composition according to any one of claims 1 to 8 and 11 and one or more cosmetically acceptable excipients.
14. A pharmaceutical formulation for antiallergic, anti-inflammatory, soothing redness, antipruritic, anti-irritant, skin repair comprising as active ingredient a compound composition according to any of claims 1-8 and 11 together with one or more pharmaceutically acceptable excipients.
15. The cosmetic or pharmaceutical formulation of claim 13 or claim 14, wherein the cosmetic or pharmaceutical formulation is a cream, lotion, paste, ointment, mask, gel, lotion or serum.
16. The cosmetic or pharmaceutical formulation according to claim 13, wherein the herbal compound composition comprises 0.1-20% by weight of the cosmetic or pharmaceutical formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210277824.8A CN114470050B (en) | 2022-03-21 | 2022-03-21 | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210277824.8A CN114470050B (en) | 2022-03-21 | 2022-03-21 | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114470050A CN114470050A (en) | 2022-05-13 |
| CN114470050B true CN114470050B (en) | 2023-09-05 |
Family
ID=81487499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210277824.8A Active CN114470050B (en) | 2022-03-21 | 2022-03-21 | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470050B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1485024A (en) * | 2002-09-28 | 2004-03-31 | 戚海波 | Bee honey and its use in beautifying cosmetics |
| CN101019952A (en) * | 2006-11-20 | 2007-08-22 | 深圳市北科联药业科技有限公司 | Medicine for treating eczema and prepn process of its ointment |
| CN110721274A (en) * | 2019-11-21 | 2020-01-24 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | External antipruritic and preparation method thereof |
| CN111588767A (en) * | 2020-07-01 | 2020-08-28 | 杭州未艾电子商务有限公司 | Grapefruit seed gynecological gel |
| CN112367969A (en) * | 2018-09-14 | 2021-02-12 | 东洋纺株式会社 | Antioxidant agent |
| CN112515999A (en) * | 2020-12-21 | 2021-03-19 | 阿谷巴(杭州)生物科技发展有限公司 | Mite and acne removing composition rich in cytokines and preparation method thereof |
| CN113244143A (en) * | 2021-05-28 | 2021-08-13 | 奢脉国际化妆品(北京)有限公司 | Soothing composition containing saxifrage extract and preparation method and application thereof |
| CN113679765A (en) * | 2021-09-30 | 2021-11-23 | 上海家化联合股份有限公司 | Cortex dictamni extract and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2007148739A1 (en) * | 2006-06-22 | 2009-11-19 | 東洋紡績株式会社 | Plant-derived cell activator, anti-aging agent, and extracellular matrix production promoter |
| WO2021005941A1 (en) * | 2019-07-05 | 2021-01-14 | 東洋紡株式会社 | Albizia julibrissin extract-containing composition |
-
2022
- 2022-03-21 CN CN202210277824.8A patent/CN114470050B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1485024A (en) * | 2002-09-28 | 2004-03-31 | 戚海波 | Bee honey and its use in beautifying cosmetics |
| CN101019952A (en) * | 2006-11-20 | 2007-08-22 | 深圳市北科联药业科技有限公司 | Medicine for treating eczema and prepn process of its ointment |
| CN112367969A (en) * | 2018-09-14 | 2021-02-12 | 东洋纺株式会社 | Antioxidant agent |
| CN110721274A (en) * | 2019-11-21 | 2020-01-24 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | External antipruritic and preparation method thereof |
| CN111588767A (en) * | 2020-07-01 | 2020-08-28 | 杭州未艾电子商务有限公司 | Grapefruit seed gynecological gel |
| CN112515999A (en) * | 2020-12-21 | 2021-03-19 | 阿谷巴(杭州)生物科技发展有限公司 | Mite and acne removing composition rich in cytokines and preparation method thereof |
| CN113244143A (en) * | 2021-05-28 | 2021-08-13 | 奢脉国际化妆品(北京)有限公司 | Soothing composition containing saxifrage extract and preparation method and application thereof |
| CN113679765A (en) * | 2021-09-30 | 2021-11-23 | 上海家化联合股份有限公司 | Cortex dictamni extract and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 阿维A胶囊联合消银颗粒治疗寻常性银屑病60例疗效观察;周英芹等;《吉林医学》;20121025(第30期);第6504-6505页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114470050A (en) | 2022-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007005886A (en) | Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant. | |
| US20150306024A1 (en) | Composition containing a natural extract | |
| JP2006111560A (en) | Ceramide synthesis promoter | |
| CN110522695B (en) | Private skin cleaning bath salt and preparation method and application thereof | |
| CN107809998B (en) | Hydroalcoholic extract of mastic from the animal of the genus mastic, cosmetic composition containing it and cosmetic use thereof | |
| MX2007014481A (en) | System and method for promoting hair growth and improving hair and scalp health. | |
| CN115887518A (en) | Anti-glycation application of sweet wormwood herb extract | |
| CN112190593B (en) | Polysaccharide composition for inhibiting TRPV1 pathway and preparation method and application thereof | |
| CN113041286B (en) | Plant anti-allergic agent for skin | |
| KR100564108B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
| CN111973515A (en) | Bacteriostatic restoration plant extraction composition, preparation method and application thereof | |
| CN106309911B (en) | Anti-aging traditional Chinese medicine composition and preparation method thereof | |
| CN114470050B (en) | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin | |
| KR20110128384A (en) | The composition material and the manufacturing process for skin-wrinkle, moisture and skin-lightening uses by midam-kyungokko | |
| CN108078903B (en) | Plant acne-removing composition and preparation method thereof | |
| CN115844939A (en) | Artemisia annua extract with TRPV1 protein inhibiting effect | |
| CN111789786B (en) | Mite-killing plant composition and preparation method and application thereof | |
| CN111568831B (en) | Composition of Chinese herbal medicine extract for skin cosmetics and preparation method thereof | |
| KR101985660B1 (en) | Cosmetic composition for treating acne containing mixed herbal extracts fermented with Nuruk | |
| KR20200120280A (en) | Cleanser composition women's vagina and method for manufacturing the same | |
| KR20200040427A (en) | Method for producing medicine of skin diseases | |
| CN114306527B (en) | Compound broadleaf holly leaf traditional Chinese medicine composition and application thereof in preparing shampoo | |
| CN115671167B (en) | Preparation method and application of traditional Chinese medicine composition with acne removing effect | |
| KR102677368B1 (en) | A skin cosmetic composition comprising illite powder and chamaecyparis obtusa leaf powder, illite extracts, chamaecyparis obtusa extracts and oriental medical plant extracts | |
| CN115282104B (en) | Plant composite extract, anti-allergic agent, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |